Summit Therapeutics (SMMT) Earnings Analysis
Summit Therapeutics (SMMT) next reports earnings on 2026-07-23, consensus EPS -0.27439 USD. Last quarter (2026-04-30) it beat with EPS -0.24 USD vs -0.33 USD est (+27.3%). It has beaten estimates in 3/6 recent quarters (50%). Trailing P/E -10.53.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does SMMT next report earnings?
| Next earnings date | 2026-07-23 |
|---|---|
| Consensus EPS estimate | -0.27439 USD |
| Revenue estimate | 0.00B |
SMMT earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-30 | -0.24 USD | -0.33 USD | +27.3% | Beat |
| 2026-02-23 | -0.29 USD | -0.10264 USD | -182.5% | Miss |
| 2025-10-20 | -0.31 USD | -0.17577 USD | -76.4% | Miss |
| 2025-08-11 | -0.76 USD | -0.09081 USD | -736.9% | Miss |
| 2025-05-01 | -0.09 USD | -0.09302 USD | +3.2% | Beat |
| 2025-02-24 | -0.08 USD | -0.08181 USD | +2.2% | Beat |
Beat rate: 3/6 (50%) over reported quarters with consensus data.
SMMT valuation and analyst view
| Trailing P/E | -10.53 |
|---|---|
| Trailing EPS | -1.35732 USD |
| Price / book | 27.61 |
| Dividend yield | 0.00% |
| Market cap | 11.53B |
| Analyst consensus | Buy (14 buy / 7 hold / 0 sell) |
| Avg price target | 19.5 USD |
Related research pages
Frequently asked questions
When is Summit Therapeutics (SMMT)'s next earnings date?
Summit Therapeutics is next scheduled to report on 2026-07-23, with a consensus EPS estimate of -0.27439 USD and revenue estimate of 0.00B.
Did SMMT beat earnings last quarter?
In its 2026-04-30 report, SMMT posted EPS of -0.24 USD versus a -0.33 USD estimate — a beat of 27.3%.
What is SMMT's earnings track record?
Over the last 6 reported quarters with consensus data, SMMT beat estimates 3 times (50%).
What is SMMT's current P/E ratio and EPS?
SMMT trades at a trailing P/E of -10.53 on trailing EPS of -1.3573150430050098 USD.
What do analysts rate SMMT?
Analyst consensus is "Buy" across 21 ratings (0 strong buy, 14 buy, 7 hold, 0 sell, 0 strong sell). Average 12-month price target: 19.5 USD.